Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Chief Advises Separate Non-COVID-19 Wards At Hospitals To Allow Device-Related Elective Surgeries To Resume

Executive Summary

To get on with the business of providing non-coronavirus procedures – including elective surgeries involving replacement joints and other non-emergency care – at US health care facilities, Medicare agency chief Seema Verma is advising hospitals and outpatient facilities to establish non-COVID-19 care (NCC) zones.

You may also be interested in...



Industry And Advocacy Groups Outline How To Restart Elective Surgeries In Midst Of COVID-19

A joint guidance from medtech, nurse and hospital advocacy groups outline recommendations for how medical device representatives can get back into hospitals to help with elective surgeries after hospitals begin shifting away from mostly treating COVID-19 patients.

Orthopedic Roundup: Zimmer Biomet, J&J, Smith & Nephew, Stryker Hope For Post-COVID Recovery As Elective Surgeries Restart

The big four companies in the orthopedics space hope that the restart of elective surgeries will make up for lost sales, but many uncertainties remain.

Interview: How Medtech Companies Are Preparing To Navigate Post-Pandemic Market

In an interview with Medtech Insight, ZS consultant Brian Chapman explains how medtech companies are handling the uncertainties created by the pandemic and how it could change the industry permanently.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

MT126631

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel